Adlai Nortye Ltd. ALN 深 滬
已收盤 08-14 16:00:00 美东时间
0.00
0.000
NaN.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 總市值 0
- 52周最高 0.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.00
- 委 比 0.00%
- 總股本 273.43万
- 歷史最高 0.00
- 量 比 0
- 振 幅 NaN.00%
- 歷史最低 0.00
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Adlai Nortye Announces $140M Private Placement Equity Financing
Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into securities
02-03 20:45
Adlai Nortye Announces $140.0 Million Private Placement Equity Financing
Adlai Nortye Ltd., a clinical-stage biotechnology company focused on innovative cancer therapies, has raised approximately $140 million through a private placement of 64,615,386 Class A ordinary shares, equivalent to 21,538,462 ADSs, priced at $2.1667 per share ($6.50 per ADS). The placement was co-led by Cormorant Asset Management and Columbia Threadneedle Investments, with participation from new and existing investors including Balyasny Asset M...
02-03 12:00
Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China
Adlai Nortye与ASK Pharm签署AN9025独家许可协议，授权其在 mainland China, Hong Kong, and Macau 开发、生产和商业化。Adlai Nortye将保留全球权利，预计获得高达16亿元人民币的总付款，包括首付款、里程碑付款及销售分成。AN9025是潜在同类最佳的pan-RAS(ON)抑制剂，针对多种肿瘤类型的RAS突变，预计2026年Q1启动I期临床试验。此次合作旨在加速RAS突变癌症患者的治疗开发。
2025-12-29 11:00
Adlai Nortye Ltd. Shareholders Approve Redomiciliation to Singapore
Adlai Nortye Ltd. Sponsored ADR ( ($ANL) ) has provided an announcement. Adlai ...
2025-12-03 19:27
Adlai Nortye to Participate in Upcoming Investor Conferences
Adlai Nortye Ltd. announced that its management team will participate in two upcoming investor conferences: the 8th Annual Evercore Healthcare Conference on December 2, 2025, in Coral Gables, Florida, and the 36th Oppenheimer Annual Healthcare Life Sciences Conference on February 25-26, 2026. The company, focused on innovative cancer therapies, is developing therapies in two key areas: next-generation cancer immunotherapies and RAS-targeting ther...
2025-11-21 13:00
Adlai Nortye Ltd. Plans Redomiciliation to Singapore
Adlai Nortye Ltd. Sponsored ADR ( ($ANL) ) just unveiled an announcement. Adlai...
2025-10-23 05:28
Adlai Nortye Announces Change in Auditing Firm
Adlai Nortye Ltd. Sponsored ADR ( ($ANL) ) has provided an announcement. Adlai ...
2025-02-14 19:57
Adlai Nortye Announces CFO Transition with Interim Appointment
An announcement from Adlai Nortye Ltd. Sponsored ADR ( ($ANL) ) is now availabl...
2025-01-01 05:28
Mazars USA LLP Agrees With Adlai Nortye Filing
Adlai Nortye Ltd. Sponsored ADR (ANL) has released an update. Adlai Nortye Ltd....
2024-06-27 18:29
Why Riot Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Riot Platforms, Inc. (NASDAQ:RIOT) rose sharply in today's pre-market trading amid a rise in Bitcoin. Bitcoin (CRYPTO: BTC) prices gained around 1.5% over the past 24 hours to $66,012 this morning.
2024-04-22 17:23
